U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Advisory Committee Calendar
  4. September 26, 2019: Meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees - 09/26/2019 - 09/26/2019
  1. Advisory Committee Calendar

Advisory Committee Meeting

Event Title
September 26, 2019: Meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees
September 26, 2019


Date:
September 26, 2019
Time:
09:00 AM - 04:40 PM EDT
Location:
Event Location
White Oak Campus: The Great Room
Conference Center

10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
United States



Agenda

On September 26, 2019, the Pediatric Advisory Committee (PAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee will meet to discuss the pediatric-focused safety review for OxyContin (oxycodone hydrochloride) extended-release tablets, as mandated by the Food and Drug Administration Safety and Innovation Act (Pub. L. 112-144), and to discuss pediatric data considerations for opioid analgesics labeling and Pediatric Research Equity Act studies for opioids generally, using Opana IR as an example.

Meeting Materials

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, all efforts will be made to try and provide the background material at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.

Background Material

Public Participation Information

On September 26, 2019 from 09:00 a.m. to 4:40 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2019-N-3617. The docket will close on September 24, 2019. Comments received on or before September 12, 2019 will be provided to the committee.  Comments received after the date will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications of information, and consider any comments submitted to the docket, as appropriate. You may submit your comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

  • Federal eRulemaking Portal:  https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
  • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submission as follows:

  • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
  • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”
  • Instructions: All submissions received must include Docket No. FDA-2019-N-3617 for “Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.”  Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
  • Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov.  Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.”  Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law.  For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Oral presentations from the public will be scheduled between approximately 1:00 p.m. and 2:00 p.m. on September 26, 2019. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 11, 2019.

Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by September 12, 2019.

Webcast Information

FDA plans to provide a free of charge, live webcast of the open session of the September 26, 2019 Joint Meeting of the PAC and DSaRM. There are instances where the webcast transmission is not successful; the staff will work to re-establish the transmission as soon as possible. Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: 2019 Meeting Materials, Pediatric Advisory Committee.

FDA plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.

Contact Information

Marieann Brill, MBA, RAC, MT(ASCP)
Office of Pediatric Therapeutics
Office of the Commissioner
Food and Drug Administration
Bldg. 32, Room 5154
10903 New Hampshire Ave.
Silver Spring, Maryland 20993
Phone: 301–240-402-3838
Fax: 301-847-8640
E-mail: marieann.brill@fda.hhs.gov

FDA Advisory Committee Information Line
1-800-741-8138
(301-443-0572 in the Washington DC area) – follow the prompts to the desired center or product area
Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s website and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.

Persons attending the FDA’s advisory committee meetings are advised that the FDA is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities. If you require special accommodations due to a disability, please contact Marieann Brill at least seven (7) days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).


Meeting Materials

Title File Type/Size Source Organization
Septemeber 26 and September 27, 2019 Drug Safety and Risk Management Roster pdf (52.88 KB)
FDA Briefing Document, 9-2019 PAC and DSRMAC Meeting pdf (3.51 MB)
Oxycontin Labeling, Revised 9/2019 pdf (492 KB)
Oxycontin Clinical Review 2015 pdf (17.43 MB)
Oxycontin Clinical Pharmacology Review 2015 pdf (18.94 MB)
Oxycontin Statistical Review 2015 pdf (582.39 KB)
Agenda for the September 26, 2019 Joint Meeting of the Pediatric adn Drug Safety and Risk Management Advisory Committees pdf (31.39 KB)
Questions for the September 26, 2019 Joint meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees pdf (14.64 KB)
Meeting Roster for the September 26, 2019 Joint meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees pdf (38.24 KB)
Pediatric Pain and the Approach to Studying Opioid Analgesics in Pediatric Populations pdf (352.47 KB)
Pediatric Utilization Patterns of Opioid Analgesics (OAs) pdf (775.7 KB)
Prescription Opioid Abuse and Related Outcomes in the Pediatric Population pdf (317.22 KB)
Pediatric Utilization Patterns of Single-Ingredient Oxycodone (Extended-Release and Immediate-Release), 2013 – 2018 pdf (289.06 KB)
Pediatric Focused Safety Review: OxyContin (oxycodone hydrochloride extended-release) pdf (759.99 KB)
Opioid Analgesics: Translating Pediatric Study Results into Labeling pdf (336.82 KB)
Prescription Opioids in Children: Importance of Accurate Labeling and Treatment of Pain pdf (1.26 MB)
Neil Chatterjee: Prescribing Controlled Substances in the Pediatric Population pdf (126.2 KB)
Josh Lloyd: Analgesics with Pediatric Labeling or Indication pdf (93.58 KB)
Josh Lloyd: Analgesics without Pediatric Labeling pdf (95.21 KB)
Transcript of the September 26, 2019 joint meeting of the FDA's Pediatric and Drug Safety Advisory Committees pdf (591.02 KB) Transcirpt of the September 26, 2019 joint meeting of the FDA's Pediatric and Drug Safety Advisory Committees
Final Meeting Minutes, September 26, 2019 Joint Meeting of the Pediatric and Drug Safety and Risk Management Advisory Committes pdf (100.17 KB) FDA

FDA Advisory Committee Information Line
1-800-741-8138
(301-443-0572 in the Washington DC area)

Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Lauren Tesh at (301) 796-9001 at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).